Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/447607

Setting Starting Level for a Trial of an Biofilm-Disrupting Adjuvant

Lodder, R. A.·Adams, B.
View original source ↗Export metadata ↓

Abstract

Combination therapy is beneficial treatment modality for multiple diseases. Cinnamon oil may be an advantageous agent in a number of combination therapies as cinnamon oil has antibacterial activity. Cinnamon oil has also been shown to be effective against biofilm cultures of Streptococcus mutans and Lactobacillus plantarum. Cinnamomum osmophloeum inhibits planktonic cultures of many gram-positive and gram-negative bacteria, including MRSA (methicillin-resistant Staphylococcus aureus). Subjecting S. epidermidis to cinnamon oil eliminates planktonic cells or staphylococci in biofilms. Cinnamon oil is an essential oil used throughout the food industry because of its pleasant and distinctive aroma. The purpose of this study is to estimate the amount of exposure to cinnamon through selected foods in the United States in order to propose an initial target level for pharmacokinetic studies of a novel combination drug.

Explore related subjects

pharmacology and toxicologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Lodder, R. A., Adams, B.. 2018-10-19. Setting Starting Level for a Trial of an Biofilm-Disrupting Adjuvant. https://doi.org/10.1101/447607

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

A Physics-Constrained Marcus-Theory Optimization Framework Restores Parameter Identifiability in Deep-Pocket Oncogenic Drug Kinetics: A KRAS G12C and STAT3 Case Study

Background: More than 90% of drug candidates fail preclinically, partly because empirical dose-response models such as the Hill equation ignore microenvironmental effects inside the deep binding pockets of targets such as mutant KRAS G12C and STAT3. Bulk water is hypothesized to raise the reorganization energy (lambda_ext). Objective: To develop a physics-constrained framework, the Cluchagues-Marcus Framework, that links local dielectric permittivity to ligand-pocket kinetics, and to determine which constraints restore parameter identifiability. Methods: Non-adiabatic Marcus kinetics were coupled to a Hill-type equation derived from a steady-state scheme, and water exclusion was modeled as a collapse of epsilon_local from 80.4 to 2.0. Pocket radii and published reference constants were used for two pockets (KRAS G12C, PDB 6UT0; STAT3 SH2, PDB 6NJS). Three propositions were proved and checked with synthetic data and a global sensitivity analysis, and the identifiability result was numerically stress-tested on real napabucasin viability curves from 701 cancer cell lines. Results: Water exclusion lowered lambda_ext by 90%. At dG = -0.10 eV, k_C rose 8.0-fold (KRAS) and 3.6-fold (STAT3). Acceleration occurs if and only if |dG| < sqrt(lambda_s x lambda_u). The model has exactly two non-identifiable parameter directions: fixing nu_eff removes one and anchoring K_d removes the other. In real curves, fits were unchanged by the K_d anchor (SSE change < 10^-7 %) while the fitted k_off,q varied by 3.5 log units, as predicted. Conclusions: A dissociation-constant anchor makes the framework identifiable. The real-data stress test is not biological validation of the dielectric mechanism, which requires experiments.

pharmacology and toxicology↗
bioRxiv2026

Gentamicin impairs nephron development in iPSC-derived kidney organoids and disrupts proximal tubular lysosomal function

Gentamicin is an aminoglycoside antibiotic used to treat Gram-negative bacterial infections. However, its clinical use is limited by nephrotoxicity, affecting approximately 10 - 20% of treated patients. Nevertheless, gentamicin remains widely used due to its high potency, low cost, and low incidence of bacterial resistance and hypersensitivity. Importantly, gentamicin crosses the placental barrier and is administered to neonates, including preterm infants in whom nephrogenesis is still ongoing, raising concerns about its effects on kidney development. Current knowledge of this risk relies largely on rodent studies, which fail to fully recapitulate human kidney physiology. Here, we developed human-relevant in vitro models to investigate the impact of gentamicin on kidney development and to unravel the dynamic cellular responses underlying gentamicin-induced impairment. Kidney organoids differentiated from induced pluripotent stem cells (iPSC) and magnetically sorted proximal tubule cells were used to model immature kidney and immature proximal cells, respectively. Organoids were continuously exposed to gentamicin (0.25 - 1.5 mM) throughout development (d7+18), while megalin-expressing proximal tubule cells were exposed for 24 hours to explore the cellular mechanisms underlying gentamicin toxicity. Intracellular concentrations of the gentamicin congeners C1, C1a, and C2/C2a/C2b were quantified by LC-MS/MS. Gentamicin exposure impaired organoid growth, and nephron formation and maturation. Additionally, gentamicin induced lipid accumulation and reduced lysosomal area in proximal tubule cells, indicating disrupted cellular metabolism and homeostasis. In conclusion, iPSC-derived kidney organoids provide a suitable platform to further investigate gentamicins impact on kidney development and studying co-treatments to mitigate its adverse effects.

pharmacology and toxicology↗
bioRxiv2026

Discovery of P1-P2 depeptidized boronic acid based Plasmodium falciparum SUB1 inhibitor

The Plasmodium falciparum subtilisin-like serine protease 1 (PfSUB1) is an essential enzyme required for parasite egress from host red blood cells and represents a promising target for antimalarial drugs. Peptidic boronic acids are potent reported PfSUB1 inhibitors, however their drug-likeness is limited by their pronounced peptidic character. Based on molecular docking studies using peptidic boronic acids, we designed a series of partially depeptidized PfSUB1 inhibitors by replacing the P1-P2 dipeptide fragment with a 3-aminomethylphenylboronic acid core. Structure-activity relationship (SAR) investigations targeting interaction with active-site residue Lys138 revealed that introducing a meta-carboxylate group (compound 3a) markedly enhanced inhibitory activity, yielding a low-nanomolar PfSUB1 inhibitor (IC50= 10.2 nM). Bioisosteric replacement of the carboxylic acid demonstrated that an N-acylsulfonamide group (compound 4k) retained high enzymatic potency (IC50= 13.5 nM)). In cellular assays against blood-stage P. falciparum (3D7 strain), the leading depeptidized boronic acids exhibited growth inhibition with values in the low-micromolar range suggesting that further structural modifications are needed to enhance membrane permeability across host and parasite membranes to reach exonemes prior to egress. Overall, this study validates the P1-P2 depeptidization of boronic acid scaffolds and provides key SAR insights for the rational design of non-peptidic PfSUB1-targeted antimalarials.

pharmacology and toxicology↗